Zenocutuzumab‑zbco Receives FDA Orphan Drug Designation for Treatment of Cholangiocarcinoma
PR Newswire —
Designation strengthens BIZENGRI® development program in rare cholangiocarcinoma LEXINGTON, Mass., Feb. 5, 2026 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx), a privately held, fully integrated biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has...